Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | IMpassion130: results of atezolizumab plus nab-paclitaxel for frontline TNBC

The breast cancer press briefing at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, presented the latest updates for three major Phase III clinical trials. Here, Peter Schmid, MD, FRCP, PhD, of Barts Cancer Institute, London, UK, gives an update on IMpassion130 (NCT02425891), which is investigating atezolizumab plus nab-paclitaxel for previously untreated triple-negative breast cancer.